pierre fabre annual report 2021


March 8, 2021 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) What were the key factors to the success of the event? The event was so successful that they envisage organizing future private Pierre Fabre Virtual Biopharma Partnering events on a regular basis to continue their partnering momentum and reputation as a partner of choice for cutting-edge biotechs. Read First Quarter Financial Results The purpose of the cookie is to determine if the user's browser supports cookies. July 1, 2019 - Puma Biotechnology Submits a Supplemental New Drug Application to U.S. FDA for Neratinib to Treat HER2-Positive Metastatic Breast Cancer August 6, 2020 - Puma Biotechnology Reports Second Quarter 2020 Financial Results Accelerate your activities throughout the entire partnering lifecycle.

It is based on a unique medical and naturalness positioning, which is reflected in various Group initiatives. Read May 9, 2017 - Puma Biotechnology to Present at Bank of America Merrill Lynch 2017 Health Care Conference June 4, 2019 - Puma Biotechnology Presents Results from Phase III NALA Trial of Neratinib in Patients with HER2 Positive Metastatic Breast Cancer at the ASCO 2019 Annual Meeting May 15, 2014 - Puma Biotechnology to Present at UBS Global Healthcare Conference December 6, 2016 - Puma Biotechnology Initiates a Managed Access Program for PB272 (Neratinib) Outside the United States We constantly strive to showcase our business model, and this new Integrated Report highlights a specific feature of our economic model: our comprehensive approach to health care prevent, treat, and support. Feb. 25, 2014 - Puma Biotechnology to Present at Cowen Health Care Conference December 6, 2018 - Puma Biotechnology Presents Results from the Phase II SUMMIT Trial of Neratinib for ERBB2 (HER2) Mutant, HER2 Non-Amplified, Metastatic Breast Cancer at the 2018 San Antonio Breast Cancer Symposium Phase III NALA Trial at the 2020 SABCS Read Read Read Read 10, 2015 - Puma Biotechnology Initiates Phase II Trial of PB272 in Early Stage HER2-Positive Breast Cancer Inovas agile Event Solutions team rapidly created a fully branded, exclusive experience for biotech attendees in One-on-One Partnering for Pierre Fabre Virtual Biopharma Partnering 2021. Read February 4, 2019 - Puma Biotechnology Announces Litigation Victory with Jurys Decision August 10, 2020 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) February 15, 2018 - Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results Read The solid internal mobilization across Pierre Fabres BD, communication and IT teams was key to getting the event off the ground. Dec. 10, 2015 - Puma Biotechnology Announces Results of Phase II Trial of PB272 in Neoadjuvant Treatment of HER2-Positive Locally Advanced Breast Cancer February 25, 2021 - Puma Biotechnology Reports Fourth Quarter and Full Year Financial Results It is intended to develop a new standard of concise reporting that combines financial and extra-financial data. Read December 7, 2016 - Puma Biotechnology Presents Results of Biomarker Analysis of Phase II Trial of PB272 in Neoadjuvant Treatment of HER2-Positive Locally Advanced Breast Cancer at the 2016 San Antonio Breast Cancer Symposium Read September 7, 2021 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Read December 11, 2018 - Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) Read Neratinib Graduates from I-SPY 2 TRIAL Read August 29, 2012 - Puma Biotechnology to Present at Stifel Nicolaus 2012 Healthcare Conference Read September 3, 2020 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) This website uses cookies to improve your experience while you navigate through the website. Read The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". April 25, 2019 - Puma Biotechnology to Host Conference Call to Discuss First Quarter Financial Results Sept. 26, 2015 - Puma Biotechnology Announces Presentation of Phase III Trial of PB272 in Extended Adjuvant Breast Cancer (ExteNET Trial) in Centrally Confirmed HER2-Positive Early Stage Breast Cancer Patients March 1, 2017 - Puma Biotechnology Provides Update on Review of Marketing Authorisation Application for PB272 The cookie is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. What was the interest level like for the event from biotechs and investors? January 13, 2020 - Puma Biotechnology Releases Slides to be Presented at the J.P. Morgan Healthcare Conference Read May 27, 2015 - Puma Biotechnology to Present at Jefferies 2015 Healthcare Conference December 11, 2019 - Puma Biotechnology Presents Results from the Phase II SUMMIT Trial of Neratinib for ERBB2 (HER2) Mutant, HER2 Non-Amplified, Metastatic Breast Cancer at the 2019 San Antonio Breast Cancer Symposium INS_2002_01, Cultivating quality of life in the workplace, Websites aimed at health care professionals, FOR THE SECOND CONSECUTIVE YEAR, PIERRE FABRE PUBLISHES ITS INTEGRATED REPORT. June 5, 2013 - Puma Biotechnology to Present at Goldman Sachs Healthcare Conference Read

January 4, 2012 - Puma Biotechnology to Present at 30th Annual J.P. Morgan Healthcare Conference Read, December 9, 2011 - Puma Biotechnology Announces Positive PB272 (Neratinib) Phase II Data at CTRC-AACR San Antonio Breast Cancer Symposium Read Dec. 4, 2013 - Puma Biotechnology Reports Positive Top Line Data from I-SPY 2 TRIAL It does not correspond to any user ID in the web application and does not store any personally identifiable information. Can you please take us through the steps of planning the event? February 25, 2021 - Puma Biotechnology and Pierre Fabre Amend NERLYNX License Agreement to Include Greater China September 21, 2021 - Puma Biotechnology to Present at the Cantor Virtual Global Healthcare Conference November 6, 2020 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Read Read Caligor Opco LLC to Provide Regulatory and Logistical Management Read May 18, 2016 - Puma Biotechnology Announces Publication of Neratinib Abstract for the 2016 ASCO Annual Meeting Read

Read Read November 4, 2021 - Puma Biotechnology Reports Third Quarter 2021 Financial Results October 18, 2018 - Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results This cookie is used for identifying the IP address of devices visiting the website.

June 1, 2015 - Puma Biotechnology Announces Phase III Trial of PB272 in Extended Adjuvant Breast Cancer (ExteNET Trial) Demonstrates Statistically Significant Improvement in Disease Free Survival Jan. 21, 2015 - Puma Biotechnology Prices Public Offering of Common Stock Read Read What key elements are required internally to ensure the success of such an event? Read Read Read Read May 9, 2013 - Puma Biotechnology Reports First Quarter 2013 Financial Results Read July 24, 2019 - Puma Biotechnology to Host Conference Call to Discuss Second Quarter Financial Results Read ABN 30 098 999 850. Read Collaborate to Study Neratinib in Various Cancers 20, 2016 - Puma Biotechnologys Neratinib Featured in Poster Presentations Read November 14, 2016 - Puma Biotechnology Announces Presentations of Investigational Data at the Read Read Read By hosting their own virtual private biopharma event that attracted visionary biotechs, Pierre Fabre was in the drivers seat to bring the partnering to their fingertips. Read Read Read Read October 22, 2020 - Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results September 7, 2021 - Puma Biotechnology to Present at the H.C. Wainwright 23rd Annual Global Investment Conference Read Read March 1, 2018 - Puma Biotechnology Reports Fourth Quarter and Full Year 2017 Financial Results August 6, 2019 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Read Their involvement from beginning to end of the project underlines their sincere attachment to the group. May 17, 2012 - Puma Biotechnology to Present Clinical Data on PB272 at ASCO 2012 Annual Meeting Read Read Would you see Biotechs/clinical during this kind of event, perhaps combine with R&D day? May 6, 2020 - Puma Biotechnology to Present at the BofA Securities Health Care Conference 2020 Read April 30, 2020 - Puma Biotechnology and Bixink Therapeutics Enter into Exclusive Licensing Agreement to Commercialize NERLYNX (neratinib) in South Korea December 2, 2020 - Puma Biotechnology, Inc. Prevails Before European Patent Office Board of Appeals in Decision Upholding European Patent (EP 1848414) as Granted

May 8, 2013 - Puma Biotechnology to Present at Bank of America Merrill Lynch 2013 Health Care Conference Read Read March 5, 2020 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) May 6, 2021 - Puma Biotechnology Reports First Quarter 2021 Financial Results Read Rule 5635(c)(4) Read Read, December 11, 2020 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) April 1, 2019 - Puma Biotechnology and Pierre Fabre Enter into Exclusive License Agreement to Develop and Commercialize NERLYNX (neratinib) in Europe Manage your due diligence process in a secure space. Mar. February 1, 2018 - Puma Biotechnology and CANbridge Life Sciences Enter into Exclusive Licensing Agreement to Commercialize NERLYNX (neratinib) in Greater China Inovas One-on-One Partnering platform powered Pierre Fabres Virtual Biopharma Partnering 2021 event, held online for the best-of-the best in the biotech community in February 2021. Providing a comprehensive overview, the 2021 integrated report underscores the crucial role played by our corporate Purpose in our on-going Transformation plan. March 28, 2019 - Puma Biotechnology Announces Publication of Abstracts on Neratinib for AACR Annual Meeting 2019 Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. May 14, 2013 - Puma Biotechnology to Present at UBS Global Healthcare Conference Read January 3, 2017 - Puma Biotechnology to Present at J.P. Morgan Healthcare Conference It allows us to provide a forward-looking vision of our organization, creating value for the benefit of patients, consumers, and stakeholders. Read Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet. at the AACR Annual Meeting 2016 Their total annual revenue in 2020 exceeded 2.3 billion, with 36% generated in France and 64% internationally. popup#due-diligence-pharma-leaders_capping. Accelerate more of the right leads with a tool built for managing your pre-CDA activities in one secure place. January 7, 2020 - Puma Biotechnology to Present at the J.P. Morgan Healthcare Conference Read The cookie is used to remember the user consent for the cookies under the category "Analytics". September 11, 2019 - Puma Biotechnology Announces U.S. FDA Acceptance of Supplemental New Drug Application for Neratinib to Treat HER2-Positive Metastatic Breast Cancer Cultivating quality of life in the workplace, The environmental and social impact of products, Making sense of scores, labels and environmental certifications, Discover the first products weve assessed, Committed to fighting cancer alongside patients, IIRC (International Integrated Reporting Council), Disclosure of Payments to Healthcare Professionals, Disclosure of Payments to Patient Organisations, Websites aimed at health care professionals, Pierre Fabre publishes its first integrated report, Its original governance guided by the public interest, Its unique positioning based on a resolutely Humanistic Purpose, Its strategy for the future, translated into a transformation plan based strongly on reinforced synergies and input from its stakeholders, Its determination to create value for its patients, consumers, health care professionals, employees and regions. Read This cookie is set by Hubspot whenever it changes the session cookie. Is another planned already? to U.S. FDA for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer November 13, 2017 - Puma Biotechnologys 5-Year Analysis of Phase III ExteNET Study Published Online in The Lancet Oncology Read Read January 15, 2021 - Puma Biotechnology Presents Interim Results from the Biliary Tract Cancers Cohort of the Phase II SUMMIT Basket Trial of Neratinib at ASCO GI August 7, 2012 - Puma Biotechnology to Present at Wedbush PacGrow Life Sciences Conference Read Read April 2, 2017 - Puma Biotechnology Launches Expanded Access Program for PB272 (Neratinib) for U.S. December 12, 2017 - Daiichi Sankyo and Puma Biotechnology Announce Research Collaboration with Major Cancer Center in HER2-Mutated Cancer May 8, 2018 - Puma Biotechnology to Present at Bank of America Merrill Lynch Health Care Conference 2018 Read Ticker symbol to remain PBYI Read Read After a thorough vetting of asset portfolios discussed with event attendees, Pierre Fabre identified a significant number of promising projects in oncology, dermatology and rare diseases brought to their private virtual table from all over the world.

May 10, 2017 - Puma Biotechnology Reports First Quarter 2017 Financial Results Read December 3, 2018 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Feb. 11, 2016 - Puma Biotechnologys ExteNET Phase III Study Published Online in The Lancet Oncology October 3, 2019 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Inova puts the information I need at my fingertips, helping me decide which partner is the best fit for my product portfolio. Read June 5, 2019 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) 18, 2016 - Puma Biotechnology Announces Publication of Abstracts on Neratinib for the AACR Annual Meeting 2016 in HER2+ Metastatic Breast Cancer January 5, 2021 - Puma Biotechnology to Present at the J.P. Morgan Healthcare Conference Read of European Opposition Proceedings March 5, 2019 - Puma Biotechnology to Present at Cowens Annual Health Care Conference Read Read June 2, 2018 - Puma Biotechnology Presents Interim Results of Phase Ib/II FB-10 Trial of PB272 in Combination with Trastuzumab Emtansine (T-DM1) in HER2-Positive Metastatic Breast Cancer at the 2018 ASCO Annual Meeting This cookie is set by linkedIn. May 9, 2012 - Puma - Merrill Lynch Health Care Conference Read Read June 7, 2013 - Puma Biotechnology Initiates Phase III Trial of PB272 (Neratinib) in HER2-Positive Metastatic Breast Cancer Patients Read July 17, 2017 - U.S. Food and Drug Administration Approves Pumas NERLYNX (neratinib) for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer May 10, 2016 - Puma Biotechnology Reports First Quarter 2016 Financial Results Jan. 4, 2016 - Puma Biotechnology to Present at J.P. Morgan Healthcare Conference Inova is built exactly for what we do, pharma partnering. Read April 2, 2017 - Puma Biotechnology Presents Interim Results of Phase Ib/II FB-10 Trial of PB272 in Combination with Trastuzumab Emtansine (T-DM1) in HER2-Positive Metastatic Breast Cancer at the 2017 AACR Annual Meeting

Read Read Read, Dec. 12, 2014 - Puma Biotechnology Announces Positive Interim PB272 (Neratinib) Phase II Data at 2014 CTRC-AACR San Antonio Breast Cancer Symposium Read July 2, 2021 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) With over 60 years of pharmaceutical expertise, Pierre Fabre is the second largest private French biopharmaceutical company and the second largest dermo-cosmetic laboratory in the world. Get the most out of conferences by boosting partnering and networking. January 29, 2021 - Puma Biotechnology Presents Interim Results from the Phase II SUMMIT Trial of Neratinib for EGFR Exon 18-Mutated, Metastatic Non-Small Cell Lung Cancer at WCLC 2020 November 1, 2018 - Puma Biotechnology Reports Third Quarter 2018 Financial Results Read December 6, 2018 - Puma Biotechnology Presents Results from the Hormone Receptor Positive Subgroup in Phase III ExteNET Trial of Neratinib for HER2-Amplified, Early Stage Breast Cancer at the 2018 San Antonio Breast Cancer Symposium Read November 9, 2017 - Puma Biotechnology Reports Third Quarter 2017 Financial Results May 7, 2014 - Puma Biotechnology to Present at Bank of America Merrill Lynch 2014 Health Care Conference Caligor Opco LLC to provide regulatory, logistical and supply chain support Furthermore, the dexterity and responsiveness of Inova teams brought Pierre Fabres private virtual partnering event to fruition rapidly and smoothly. Read Feb. 24, 2015 - Puma Biotechnology to Present at Cowen Health Care Conference Read July 1, 2021 - FDA Approves Dose Escalation Label Update for Puma Biotechnologys NERLYNX (neratinib) in HER2-Positive Early Stage and Metastatic Breast Cancer The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertisement". Read Whats more, a virtual format enabled travel expense cost-cutting and partnering meetings to be scheduled into a normal working day and across time zones. Read There are many possibilities to configure and organize a virtual biopharma private partnering event with Inova's One-on-One Partnering. Read But opting out of some of these cookies may affect your browsing experience. Read

Inovas Event Solutions team is ready to think outside of the box to make these events a success for hosts and attendees alike. Read Nov. 3, 2015 - Puma Biotechnology to Present at Credit Suisse Healthcare Conference 14, 2016 - Puma Biotechnologys NEfERT-T Phase II Study Published Online in JAMA Oncology One-on-One Partnering facilitates hundreds of thousands of face-to-face meetings, small and large, virtual and in-person, including Inova and BIOs Virtual Partnering series and the BIO International Convention. Read Read September 4, 2018 - European Commission Grants Marketing Authorisation for Puma Biotechnology's NERLYNX (neratinib) for Extended Adjuvant Treatment of Hormone Receptor Positive HER2-Positive Early Stage Breast Cancer January 19, 2021 - Puma Biotechnology to Present at the B. Riley Oncology Investor Conference October 2, 2018 - Puma Biotechnology's Licensing Partner CANbridge Pharmaceutical Submits New Drug Application for NERLYNX (neratinib) in China Read January 23, 2018 - Puma Biotechnology Announces Results of CHMP Oral Explanation for Neratinib for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer Far from being put on hold, the Transformation Plan is at work in the highly concrete projects featured in the Integrated Report. It contains the domain, initial timestamp (first visit), last timestamp (last visit), current timestamp (this visit), and session number (increments for each subsequent session). Read Can you describe the screening process for the companies that participated? May 31, 2017 - Puma Biotechnology to Present at the Jefferies 2017 Healthcare Conference These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc. February 13, 2019 - Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results July 22, 2014 - Puma Biotechnology Announces Amendment to Neratinib Licensing Agreement with Pfizer June 2, 2020 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) October 2, 2019 - FDA Approves Labeling Supplement for Puma Biotechnologys NERLYNX (neratinib) for the Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer

August 6, 2021 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) May 30, 2018 - Puma Biotechnology to Present at Jefferies Global Healthcare Conference Inova bridges the challenge of two externally-facing function within AstraZeneca, R&D and Business Development, and gets them operating in a seamless fashion: the right hand knows what the left hand is doing. Read 424-248-6501 Fax. Read Read Read Analytical cookies are used to understand how visitors interact with the website. Sept. 3, 2014 - Puma Biotechnology Announces Late-Breaking Oral Presentation on Neratinib in NSCLC with HER2 Mutations at ESMO 2014 July 31, 2017 - Puma Announces Availability of NERLYNX (neratinib) for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer in the United States Read ReadMay 29, 2019 - Puma Biotechnology to Present at Jefferies 2019 Global Healthcare Conference Read May 30, 2012 - Puma Biotechnology to Present at Jefferies Healthcare Conference Read Nov. 12, 2013 - Puma Biotechnology Reports Third Quarter 2013 Financial Results Read March 18, 2019 - Puma Biotechnology Presents Interim Results from the Phase II SUMMIT Trial of Neratinib for HER2 (ERBB2) Mutant, Metastatic Cervical Cancer at the Society of Gynecologic Oncology (SGO) 2019 Annual Meeting - Oral Plenary Presentation Receives SGO Presidential Award March 1, 2017 - Puma Biotechnology Announces Publication of Abstracts on Neratinib for the AACR Annual Meeting 2017 Read Read Read Read Tha Open Innovation Uses Inova as Their Single Source of Truth for Partnering, Zambon Maximizes the Value of Their Distribution Partnerships with Inova, Novo Nordisk Implements S&E Best Practices with Inova. Read In parallel, Pierre Fabre activated a highly effective social media campaign to attract pioneering biotechs to participate at their private event. Feb. 5, 2015 - Puma Biotechnology to Present at Leerink Global Healthcare Conference Read Vi engagerar oss i vrd av kroniska sjukdomar, Vi engagerar oss i vrd av vardagliga kommor, Vi str vid patienternas sida i kampen mot cancer, Offentliggrande av betalningar till sjukvrdspersonal, Webbplatser som riktar sig till hlso- och sjukvrdspersonal, Rapportera reaktion av en kosmetisk produkt, Fr dig som arbetar inom hlso- och sjukvrden, FOR THE SECOND CONSECUTIVE YEAR, PIERRE FABRE PUBLISHES ITS INTEGRATED REPORT. Read Read December 11, 2017 - Puma Biotechnology Announces Positive Outcome of European Opposition Proceedings The purpose of the cookie is to enable LinkedIn functionalities on the page. February 20, 2020 - Puma Biotechnology Reports Fourth Quarter and Full Year Financial Results Read Read April 4, 2019 - Puma Biotechnology Expands Cohorts in Phase II SUMMIT Trial of Neratinib in Cancer Patients with Tumors with Activating EGFR or HER2 Mutations Read Read June 5, 2016 - Puma Biotechnology Presents Positive Phase II Data at the 2016 ASCO Annual Meeting This cookie is a browser ID cookie set by Linked share Buttons and ad tags. The BD and AM teams were already using Inova and happy with it. April 3, 2020 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Phase I Results Demonstrate Safety and Efficacy of PB272 in Combination with Paclitaxel and Trastuzumab in Women with Metastatic HER-2 Positive Breast Cancer Read May 17, 2013 - Puma Biotechnology Comment on Trading Activity Read Read February 8, 2017 - Puma Biotechnology to Present at LEERINK Partners Global Healthcare Conference November 2, 2017 - Puma Biotechnology Secures $100 Million Term Loan from Silicon Valley Bank and Oxford Finance Read November 23, 2021 - Puma Biotechnology Announces U.S Patent Term Extension for NERLYNX (neratinib) They underline how we successfully balance financial results and non-financial performance. The award-winning conference partnering system for Life Sciences events that biotech and pharma love. After all, creating value only has any worth when it is shared by everyone. June 4, 2021 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) August 9, 2016 - Puma Biotechnology Reports Second Quarter 2016 Financial Results May 19, 2021 - Puma Biotechnology Announces Publication of Abstracts on Neratinib for the 2021 ASCO Annual Meeting Today, Pierre Fabre published its first integrated annual report: a comprehensive overview of the value created by the Group for all of its stakeholders. Read Read Read Read September 8, 2020 - Puma Biotechnology to Present at the H.C. Wainwright 22nd Annual Global Investment Conference Read Read On top of these specific technical prerequisites, the platform and event organization needed to be delivered and executed rapidly and smoothly within a tight timeframe of three months. December 10, 2021 - Puma Biotechnology Presents Updates from the SUMMIT Trial at the 2021 SABCS Annual Meeting Read Read August 5, 2021 - Puma Biotechnology Reports Second Quarter 2021 Financial Results Necessary cookies are absolutely essential for the website to function properly. -NDA Filing Currently Anticipated for Q1 2016 August 9, 2018 - Puma Biotechnology Reports Second Quarter 2018 Financial Results Read Read September 20, 2018 - Puma Biotechnology to Present at Cantor Global Healthcare Conference Apr. Read Read September 6, 2018 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Dec. 18, 2015 - Puma Biotechnology Expands Third Cohort in Phase II Trial of PB272 in HER2 Mutation Positive Cancer Patients What could you improve in a future private partnering event? Read July 26, 2021 - Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital September 3, 2019 - FDA Grants Orphan Drug Designation to Puma Biotechnologys NERLYNX for the Treatment of Breast Cancer Patients with Brain Metastases November 5, 2020 - Puma Biotechnology Announces Interim Results from the Phase II SUMMIT Trial of Neratinib for EGFR Exon 18 Mutated, Metastatic Non-Small Cell Lung Cancer February 7, 2018 - Puma Biotechnology to Present at LEERINK Partners Global Healthcare Conference November 9, 2016 - Puma Biotechnology Reports Third Quarter 2016 Financial Results In addition to certain standard Google cookies, reCAPTCHA sets a necessary cookie (_GRECAPTCHA) when executed for the purpose of providing its risk analysis. February 28, 2020 - Puma Biotechnology to Present at Cowens Annual Health Care Conference Read The ultimate objective of an integrated report is to provide clearer information about the Groups value creation in the short, medium and long term, or in other words, about the companys ability to adopt a more sustainable model. January 9, 2020 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Apr. In the wake of a virtual JP Morgan Healthcare Conference in January 2021 held during a challenging COVID-19 context, Pierre Fabre realized they needed to take partnering into their own hands and create their own space to accelerate in-licensing activities with biotechs: the Pierre Fabre Virtual Biopharma Partnering 2021 event.